Journal of Nanomaterials / 2013 / Article / Tab 2

Review Article

Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials

Table 2

Half-life of ASNase (native versus PEGylated) [50].


E. coli native ASNase (Elspar)Merck & Co. Inc.1.15 days
PEG-ASNase (Oncaspar)Enzon Pharmaceuticals5.85 days

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.